Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia

Assessment of efficacy of vardenafil in subjects with erectile dysfunction and diabetes, hypertension or...

Date First Received: April 24, 2008

Last Updated: April 27, 2008

Verified by: Bayer, April 2008

Clinical Trial Phase: Phase 3 | Start Date: December 2003

Overall Status: Completed

Estimated Enrollment: 530

Brief Summary

Official Title: “A Randomized, Open-Label, Multi-Center, Parallel Group Study to Investigate the Efficacy and Safety of Vardenafil in Comparison to Tadalafil in Males With Erectile Dysfunction and a Diagnosis of Diabetes, Hypertension or Hyperlipidemia”

Condition Keyword(s):

Assessment of efficacy of vardenafil in subjects with erectile dysfunction and diabetes, hypertension or hyperlipidemia

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Intervention(s) in this Clinical Trial

  • Drug: Levitra (Vardenafil, BAY38-9456)
    • 10 mg one hour prior to sexual intercourse
  • Drug: Tadalafil
    • 10 mg taken approximately 24 hours prior to sexual intercourse

Arms, Groups and Cohorts in this Clinical Trial

  • Experimental: Arm 1
  • Active Comparator: Arm 2

Outcome Measures for this Clinical Trial

Primary Measures

  • Sexual encounter profile question 3 observed within 15 minutes to 4 hours for vardenafil and 22 to 26 hours for the tadalafil group
    • Time Frame: 4 weeks
      Safety Issue?: No

Secondary Measures

  • Sexual encounter profile question 2
    • Time Frame: 4 weeks
      Safety Issue?: No
  • Hardness of erection
    • Time Frame: 4 weeks
      Safety Issue?: No
  • Other diary based variables
    • Time Frame: 4 weeks
      Safety Issue?: No
  • Safety and tolerability
    • Time Frame: 4 weeks
      Safety Issue?: Yes

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Age: 18 years and older
  • Males with erectile dysfunction
  • Stable heterosexual relationship
  • Medical history / diagnosis of diabetes mellitus and/or hypertension and/or hyperlipidemia

Exclusion Criteria:

  • Primary hypoactive sexual desire
  • History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months
  • Nitrate use
  • Other exclusion criteria apply according to Summary of Product Characteristics

Gender Eligibility for this Clinical Trial: Male

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: Bayer

Overall Clinical Trial Officials and Contacts

Bayer Study Director Study Director Bayer  

Additional Information

Information obtained from ClinicalTrials.gov on August 21, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00668109

Study ID Number: 10893

ClinicalTrials.gov Identifier: NCT00668109

Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Click here to find results for studies related to marketed products

Click here and search for drug information provided by the FDA

Click here and search for information on any recalls, market or product safety alerts by the FDA

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.